TKT and non-small cell lung carcinoma: Although gefitinib-susceptible cases are observed in a small number of NSCLC patients, sensitive response to treatment with gefitinib could be associated with several mutations in the TK domain of EGFR, such as the L834R mutation which is the hot spot mutation in NSCLC patients that enhances kinase activity.